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Due to the introduction of active HIV antiretroviral treatment, AIDS-related morbidity and mortality have markedly decreased
and liver diseases are now a major cause of morbidity and mortality in HIV-infected patients. Chronic liver injury encompasses
a wide spectrum of diseases due to HCV and HBV coinfection, drug-related toxicity, and NASH. HIV-infected patients who are
receiving treatment present with a high prevalence of metabolic complications and lipodystrophy. Those patients are at high risk
of nonalcoholic fatty liver disease, the liver feature of the metabolic syndrome. This review will focus on (1) the liver injuries in
HIV-infected patients; (2) both the current experimental and human data regarding PPAR and liver diseases; (3) the interactions
between HIV and PPAR; (4) the potential use of PPAR agonists for the management of HIV-related liver diseases.
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1.Introduction
The eﬃcacy of highly active antiretroviral treatment
(HAART) has resulted in a considerable improvement in the
life expectancy of HIV-infected patients. As a consequence,
liver diseases have emerged as a key issue in the management
of HIV-infected patients, and they are now a major cause of
morbidity and mortality [1]. Chronic liver injuries in HIV-
infected patients encompasses a wide spectrum of liver dis-
eases mostly consisting of coinfection with hepatitis B and C
viruses,excessivealcoholconsumption,drug-relatedtoxicity,
and more recently identiﬁed fatty liver disease. Over the last
few years, a set of metabolic alterations has also emerged
in HIV-infected patients treated with HAART, including
the lipodystrophy syndrome, which is closely associated
with insulin resistance. The syndrome typically associates
visceral fat hypertrophy, limb lipoatrophy, dyslipidemia,
and insulin-resistance, thereby resembling a caricature of
the metabolic syndrome. Those patients are at high risk
of nonalcoholic fatty liver disease, the liver feature of the
metabolic syndrome.
Peroxisome proliferator-activated receptors (PPAR) con-
stitute a family of nuclear receptors, some of them being
expressed in the liver. They are involved in glucose and lipid
metabolism, in insulin sensitivity [2] and in many other
physiological processes, particularly inﬂammation ﬁbrogen-
esis [3] and carcinogenesis. Experimental and human data
have portrayed PPAR as potential molecular players in
chronic liver diseases. Interactions between some HIV pro-
teins and PPAR reinforce the potential role of these nuclear
receptorsinthedevelopmentofHIV-associatedliverinjuries.
In addition, the development of new nonhepatotoxic ligands
made it possible to use PPAR agonists as new therapeutic
targets in liver diseases. For these reasons, studies in the ﬁeld
of PPAR are of high concern, not only to basic researchers
but also to clinicians for the management of liver diseases.
Thisreviewwillfocuson(1)theliverinjuriesinHIV-infected
patients; (2) both the current experimental and human
data regarding PPAR and liver diseases; (3) the interactions
between HIV and PPAR; (4) the potential use of PPAR
agonists for the management of HIV-related liver diseases.
2. LiverInjuriesinHIV-InfectedPatients:
Which DiseaseHasWhich Prevalence?
2.1. Coinfection with Hepatitis B and C. Due to their
common routes of transmission, chronic hepatitis B and C2 PPAR Research
viruses are often associated with HIV infection and are
present in 10% and 30% of HIV-infected patients, respec-
tively.
It has been clearly established that HIV infection sig-
niﬁcantly changes the natural history of HBV and HCV
by enhancing their viremia levels [4]. HIV also worsens
the histological course of HBV and HCV by increasing the
severity of ﬁbrosis and accelerating the risk of cirrhosis and
hepatocellular carcinoma [5, 6].
2.2.ExcessiveAlcoholConsumptionandDrug-RelatedToxicity.
Excessive alcohol consumption has been observed in one-
third of HIV-infected patients [5, 7]. In addition, alcoholic
hepatitis is more frequent and more severe, suggesting a
speciﬁc sensitivity to alcohol in HIV-infected patients [8].
All classes of antiretroviral drug have been associated
with liver toxicity. Drug-related toxicity is more frequent
in patients treated with some nonnucleoside reverse tran-
scriptase inhibitors (NNRTIs) or protease inhibitors (PIs)
and in patients with preexisting liver injuries due to alcohol,
HBV, or HCV [9]. Some nucleoside reverse transcriptase
inhibitors(NRTIs)areabletoinducemicrovesicularsteatosis
with lactic acidosis, potentially leading to hepatic failure
[10].
2.3. Nonalcoholic Fatty Liver Disease: An Underestimated
Cause of Liver Injury in HIV-Monoinfected Patients. Steato-
sis, the main feature of fatty liver, is deﬁned as abnormal fat
accumulation in hepatocytes related to metabolic abnormal-
ities and insulin resistance, toxic injuries (alcohol, drugs),
or viral infections, in particular with HCV. Nonalcoholic
fatty liver disease (NAFLD,) also called metabolic liver
disease, has become the most common cause of chronic liver
injury in HIV-uninfected patients [11], with an estimated
prevalence in the general population ranging from 14% to
31% [12–14]. One-third of those patients have histologic
signs of ﬁbrosis and necroinﬂammation, indicating the
presence of nonalcoholic steatohepatitis (NASH) [11]. Such
liver injuries are likely to lead to cirrhosis, liver, failure and
hepatocellular carcinoma. Insulin resistance plays a central
role in the development of liver steatosis, but the precise
molecular mechanisms leading to steatohepatitis and ﬁbrosis
remain undeﬁned.
Lipodystrophy is a frequent long-term side eﬀect of
antiretroviral therapy, being reported in 40 to 50% of
HIV-infected patients receiving HAART [15]. As a result
of insulin resistance and/or visceral fat hypertrophy, HIV
patients with HAART-related lipodystrophy are considered
at risk of NAFLD. In addition, NAFLD has been recently
demonstratedtobeanearlymarkerofcardiovasculardisease,
which has also become an emergent issue in HIV-treated
patients with HAART over the last decade [16]. These
data underscore the importance of assessing the presence
of NAFLD in HIV-infected patients with antiretroviral
treatment who are particularly at risk of metabolic disorders.
In HIV-monoinfected patients with HAART-related
lipodystrophy, few data are available on the true incidence
of NAFLD and most of the studies used indirect tools for the
diagnosis of steatosis, whereas the benchmark is histologic
assessmentofliverfatcontentthroughtheuseofbiopsy[13].
Indirect evidence of fatty liver has been suggested in HIV
patientswithlipodystrophybydemonstrationofasigniﬁcant
correlation between alanine aminotransferase (ALT) serum
levels and insulin resistance [17]. However, it is thought
that liver injury is poorly correlated with liver enzyme
serum levels in patients with NAFLD [18]. By using proton
spectroscopy, Sutinen et al. found increased liver fat related
to the severity of insulin resistance in 25 HIV patients with
lipodystrophy [19]. Moreno-Torres et al. found intrahepatic
triglycerides deposits in 17 of 29 HAART recipients, 4 of
whom (13.8%) had liver fat contents compatible with the
diagnosis of liver steatosis [20]. More recently, Hadigan
et al. identiﬁed hepatic steatosis in 42% of their patients
[21]. Mohammed et al. demonstrated that HIV-infected
patientswithNAFLDhadlowerbodymassindicesthanHIV-
seronegative patients [22], suggesting that NAFLD may be
associated with factors other than those classically observed
in obesity, including direct HIV infection and antiretroviral
therapy. Among 225 HIV-infected patients enrolled in a
recent study, 83 (36.9%) were diagnosed with NAFLD using
tomodensitometry [23].Two studies usedliver biopsy for the
diagnosisofunexplainedchronictransaminaseelevationand
NASH was observed in over half of HIV-infected patients
in the absence of other causes of chronic liver diseases,
with a close association with insulin resistance [24, 25].
Guaraldi et al. [23] showed that NAFLD was associated
with lipodystrophy and waist size, suggesting a relationship
between adipose tissue, insulin resistance, and fatty liver. In
light of these studies, NAFLD may be considered a common
liver disease in HIV-monoinfected patients. HAART-related
insulin resistance and lipodystrophy likely play a major
etiologicrolebuttheirmechanismsremaintobedetermined.
Some PPARs are expressed in the liver, the central organ
in the balance of glucose and lipid metabolism, and as
a result they could be involved in metabolic-related liver
injuries.
2.4. PPAR and Liver Injury. PPAR are transcription factors
belonging to the family of nuclear receptors [26]. When
activated by ligand binding, PPAR are able to activate
promoters and to modulate the expression of target genes.
They exist in three isoforms, PPARα,P P A R β/δ,a n dP P A R γ.
This review will focus on PPARα and PPARγ, as the
functions of PPARβ/δ in glucose and lipid metabolism are
less established.
PPARα is highly expressed in the liver, and its functions
are better documented than those of PPARγ which are
synthesized at lower levels. PPARα is the most abundant
nuclear receptor in the liver and is mainly expressed by the
hepatocytes [27] though also by the stellate cells, biliary cells,
endothelial cells, and Kupﬀer cells [3, 28–30].
These nuclear receptors are involved in glucose and lipid
metabolism and also in nonmetabolic functions including
inﬂammation,tissuerepair,cellproliferation,diﬀerentiation,
carcinogenesis, and ﬁbrosis [3, 31, 32]. Several studies
mostly conducted in vitro and in animal models have
suggested that these nuclear receptors could be involved
in the development of liver injuries including steatosis,PPAR Research 3
inﬂammatory injuries, and ﬁbrosis. There is very little data
available on PPAR expression and functions in HIV-infected
livers. As no data have been published in HIV/HCV or
HIV/HBV coinfected patients, this review will focus on HIV-
monoinfected patients, particularly those with metabolic
disorders.
2.5. PPAR and Steatosis. Steatosis is closely associated with
insulinresistanceandimpairmentofglucoseandlipidhome-
ostasis.ActivationofPPARαdirectlyregulatesgenesinvolved
in fatty acid uptake by increasing the expression of the fatty
acid transport protein (FATP) and the fatty acid translocase
(FAT) [33]. PPARα also promotes fatty acid oxidation in the
peroxisomes, as well as in the mitochondria, reducing the
fatty acid pool available to the liver for triglyceride synthesis
[34]. In addition, PPARα activation decreases triglyceride
levels by enhancing lipoprotein lipase (LPL) expression [35]
and by inhibiting apolipoprotein C-III in the liver [36].
Activators of PPARα include diverse chemicals such as
endogenous molecules (fatty acids/steroids) and xenobiotics
(ﬁbrate lipid-lowering drugs) [37–39].
The potential role of PPARα in the development of liver
steatosis is mostly based on experimental data conducted
in murine lacking PPARα.P P A R α−/− mice display obesity
and serious liver steatosis without excessive food intake and
PPARα activation by ﬁbrates reverses insulin resistance and
reduces weight [40]. There is a little data available in the
human liver on PPARα liver expression and its role in liver
diseases. In chronic hepatitis C with steatosis, reduced levels
of PPARα mRNA have been demonstrated [41]. In HIV-
infected patients with HAART-related lipodystrophy and
NAFLD, Lemoine et al. did not observe changes in the liver
expression of PPARα mRNA compared to NASH patients
withoutHIVandtonormallivercontrols[24].Noadditional
data have been published on human liver disease to date.
PPARγ is a transcription factor that regulates the gene
expression involved in lipid metabolism and in adipocyte
diﬀerentiation[42].PPARγ ishighlyexpressedintheadipose
tissue under two isoforms (PPARγ1a n dP P A R γ2) that are
generated by the same gene through altering splicing [43].
Whereas the functions of PPARγ are well established in the
adipose tissue, they remain hypothetical in the liver.
PPARγ activation plays a role in various physiological
and pathological events, including adipocyte diﬀerentiation,
insulin sensitivity and regulation of lipid metabolism. The
natural ligands of PPARγ remain unknown. There is evi-
dence that small lipophilic compounds, such as polyunsat-
urated fatty acids and fatty acid derivatives (eiocosanoids),
bindandactivatePPARγ [44].Thiazolinedionesaresynthetic
ligandsusedasantidiabeticdrugs,astheyhavebeenreported
to enhance insulin sensitivity [45]. In animal as well as
in human livers, PPARγ levels are much lower than those
of PPARα. Several murine models of obesity and diabetes,
including ob/ob, A-ZIP, aP2/DTA, and KKAy have been
shown to develop fatty livers that express high levels of
liver PPARγ mRNA [46, 47]. In addition, mice lacking
PPARα−/−,whichdevelopliversteatosis,alsoexpressedhigh
hepatic PPARγ mRNA [40]. These results suggest a potential
etiologicroleofPPARγ infattyliverdisease.Fewstudieshave
been conducted in human livers. PPARγ is expressed at low
levels and its expression is decreased in HCV-monoinfected
patients [41] and HIV-infected patients [24].
2.6. PPAR and Inﬂammation. Many experimental data are
in favor of anti-inﬂammatory activities of PPAR. PPARα
and PPARγ have been shown to downregulate inﬂammatory
response genes by inhibiting the STAT, AP-1, and NF-
κB transcriptional pathways in human hepatocytes and
monocytes [31, 48, 49]. In primary human hepatocytes,
Delerive et al. suggested the anti-inﬂammatory eﬀects of
ﬁbrates, which are PPARα agonists, by increasing IκB
expression and antagonizing NF-κBa c t i v a t i o n[ 49]. By
regulating antioxidant enzyme activities, such as catalase,
PPARα agonists may also reduce the oxidative stress [50].
These anti-inﬂammatory eﬀects have also been vali-
dated in vivo. Acute hepatitis induced in PPARα−/− or in
PPARγ+/− animals is particularly severe with exacerbation
of liver inﬂammatory injury [51, 52]. One of the suggested
mechanisms is the ability of PPARα activation to inhibit the
nucleartranslocationofNF-κB[49].InliversofPPARαwild-
type mice, treatment with ﬁbrates resulted in IκB induction,
whereas no increase was observed in PPARα null mice [49].
Not only in alcoholic models of rats and mice but also
in hepatocytes treated with ethanol and acetaldehyde, Lee
et al. recently showed a downregulation of PPARα mRNA
[53]. In humans treated with fenoﬁbrate, a decreased level
of blood cytokines (TNFα,I L - 6 ,I F N γ)w a sf o u n d[ 54]. No
relationship has been demonstrated between the extent of
PPAR expression and liver inﬂammation in human livers.
2.7. PPAR and Liver Fibrosis. PPARγ has been shown to be
expressed in quiescent hepatic stellate cells (HSCs) and its
expression and activity are decreased during HSC activation
in rats in vitro and in vivo [3, 28, 55]. The treatment of rat
HSCwithPPARγ ligandspreventstheiractivationinvitro.In
addition, the in vivo treatment of rats with synthetic PPARγ
agonists prevents ﬁbrosis induced by toxic or bile duct
ligation [3, 56]. However these eﬀects remain controversial
considering the results of contradictory studies [57, 58]. A
human study has suggested an antiﬁbrogenic eﬀect induced
by a synthetic agonist (pioglitazone) [59]. In HIV-infected
patients with NAFLD, it has been shown that hepatic PPARγ
expression was signiﬁcantly decreased compared to controls
withnormalliverhistologyandwasinverselyrelatedtoﬁbro-
sis [24]. In light of those results, PPARγ agonists appear to be
compelling drugs for the prevention of liver injury related to
insulin resistance. PPARα could be involved in ﬁbrogenesis
through adiponectin activation, as this adipokine could have
antiﬁbrogenic properties. Adiponectin has been shown to
enhance PPARα activation through the AMP-kinase pathway
in animal models of cardiac ﬁbrosis [60]. In HIV patients,
a hepatic decrease of PPARγ mRNA has been shown to be
related to the presence and the severity of liver ﬁbrosis [24].
3. InteractionsbetweenHIV andPPAR
3.1. Eﬀects of HIV Infection on PPAR Activity. The possibility
thatHIV-1infectioncouldinﬂuencePPARγ activityhasbeen
established through in vitro studies.4 PPAR Research
In a recent study, HIV-1 viral protein r (Vpr) was
shown to suppress the transcriptional activity of PPARγ in
mouse adipocytes. HIV could directly alter insulin sensitivity
by suppressing PPARγ activity [61]. The HIV Nef protein
involved in viral replication has been shown to suppress
PPARγ expression [62].
3.2. Eﬀects of PPAR on HIV. The ability of nuclear receptors
to interact with the long-terminal of HIV-1 was recognized
several years ago [63]. RXR and PPARα were seen to bind a
region between −356 to −320 in the long terminal repeat.
In addition, PPARα agonists such as cloﬁbrate have been
shown to activate HIV-1 transcription [64]. Fenoﬁbrate,
another PPARα agonist also has properties that inhibit HIV
replicationandTNFαproductioninalveolarmacrophagesof
HIV-infected patients [65].
In HIV-infected macrophages, natural and synthetic
PPARγ agonists inhibit HIV replication [60, 66]. More
recently, it has been reported that HIV-1 replication was
inhibited by ciglitazone, a PPARγ agonist, in a dose-
dependent manner in acutely infected human monocyte-
derived macrophages and in latently infected and viral entry-
independentU1cells,suggestinganeﬀectatthelevelofHIV-
1 gene expression [66]. Cotransfection of PPARγ wild-type
vectors and treatment with PPARγ agonists inhibited HIV-1
promoter activity in U937 cells,and activation of PPARγ also
decreased HIV-1 mRNA stability following actinomycin D
treatment[67].SimilarresultswereobservedbySkolniket al.
In this study, PPARα and PPARγ agonists decreased HIV-
1 replication in peripheral blood monocular cells infected
with HIV-1, in chronically infected monoblastoid cells and
in alveolar macrophages from HIV-1 patients and controls
[65]. The mechanisms of action by which PPAR acts on
HIV-1 remain unknown. A direct eﬀect on speciﬁc regions
on HIV-1 and indirect eﬀects via NF-κBh a sb e e np r o p o s e d
[68].
3.3. PPAR Agonists as a New Therapeutic Path. Management
of liver damage in HIV-infected patients requires increasing
attention in regard to the growing liver-related mortality
in these patients. The cofactors that are likely to worsen
liver injuries need to be eradicated when possible: viral
infection, alcohol, drug toxicity, overweight, and metabolic
abnormalities. Lipodystrophy syndrome associated with
insulin resistance plays a role in the development of fatty
liver disease. By enhancing insulin sensitivity, PPARγ ago-
nists or thiazolinediones are used for the treatment of
type 2 diabetes. In addition, beneﬁts of these drugs have
been suggested from experimental data conducted in vitro
with PI-treated adipocytes [69]. As a consequence, several
studies have been performed to evaluate the beneﬁts of
thiazolinediones in lipodystrophic HIV-infected patients.
A recent study has evaluated the beneﬁts of a treatment
with pioglitazone (30mg/d) compared to placebo among
130 HIV-infected patients with lipoatrophy. There was an
increased amount of limb fat, but no signiﬁcant diﬀerence in
visceral abdominal fat, and the lipid proﬁle (increased high-
density lipoprotein) was improved [70]. Recent studies have
suggested positive eﬀects of thiazolinediones on steatosis and
possibly ﬁbrosis in NAFLD patients without HIV infection
[59,71].Assessmentofthebeneﬁtsofpioglitazoneoninsulin
resistance and liver injuries in HCV-infected patients is
in progress (http://clinicaltrials.gov/show/NCT001891633).
The main obstacle to using thiazolinediones is their cardio-
vascular side-eﬀects, particularly in patients with increased
cardiovascular risks, such as the HIV-infected patients
treated with HAART. Such beneﬁts need to be assessed
in monoinfected and coinfected HIV-infected patients with
fatty liver disease.
Fibrates are synthetic ligands of PPARα, and they have
been used for years in the treatment of lipid disorders. In
HIV-infected patients, ﬁbrates are eﬃcient and safe in diet-
resistanthyperlipidemia[72].Inasmallcohortofuninfected
patients with NAFLD, fenoﬁbrate has been demonstrated
to improve metabolic syndrome and liver tests without
signiﬁcant eﬀects on liver histology [73].
The recently discovered endocannabinoid system con-
tributes to the physiological regulation of food intake and
glucose and lipid balance and is overactive in obese subjects.
Two types of receptors have been described, CB1 and CB2,
and are expressed in numerous tissues including the liver.
An antagonist of CB1, called rimonabant, has been shown
to induce weight loss and improve metabolic disorders
in animals and humans [74]. In addition, this treatment
could have antiﬁbrogenic eﬀects [75]. Interactions between
the endocannabinoid system and PPARγ ligands have been
established, opening a new path for the management of
metabolic-related liver injuries [76].
4. Conclusions
Liver diseases in HIV-infected patients both with and
without viral hepatitis coinfection have received increasing
attention in recent years. Metabolic disorders including
insulin resistance, lipodystrophy, and NAFLD are long-term
side eﬀects that are frequently observed in HIV-infected
patients receiving HAART.
Since the discovery of PPAR in 1990, signiﬁcant progress
has been made in understanding their eﬀects and their
potential roles in human disease and in metabolism alter-
ations in particular. Animal and human experimental data
have provided strong evidence for establishing a patho-
physiological link between PPAR and NAFLD. Although
the molecular mechanisms remain unclearly deﬁned, direct
reciprocal interactions between the virus itself and PPAR
reinforce the hypothesis for the role of these transcription
factors in the control of liver injury, particularly in steatosis,
inﬂammation, and ﬁbrosis. The existence of natural and
synthetic ligands of PPAR opens new therapeutic options for
the management of metabolic disturbances in HIV-infected
patients with HAART-associated lipodystrophy, often associ-
ated with liver diseases.
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